HSBC Holdings
ANIK icon

HSBC Holdings’s Anika Therapeutics ANIK Stock Holding History

HSBC Holdings’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$727K Sell
50,105
-187
-0.4% -$2.77K ﹤0.01% 2104
2026
Q1 		$729K Buy
50,292
+1,951
+4% +$22.6K ﹤0.01% 2035
2025
Q4 		$464K Buy
+48,341
New +$463K ﹤0.01% 2353
2024
Q2 		– Sell
-10,830
Closed -$275K – 2925
2024
Q1 		$275K Buy
10,830
+470
+5% +$11.4K ﹤0.01% 2496
2023
Q4 		$232K Sell
10,360
-932
-8% -$19.3K ﹤0.01% 2398
2023
Q3 		$209K Buy
+11,292
New +$234K ﹤0.01% 2397
2021
Q1 		– Sell
-6,797
Closed -$304K – 2712
2020
Q4 		$304K Buy
6,797
+991
+17% +$37.6K ﹤0.01% 2557
2020
Q3 		$202K Sell
5,806
-67
-1% -$2.42K ﹤0.01% 2467
2020
Q2 		$222K Buy
+5,873
New +$193K ﹤0.01% 2298

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

HSBC Holdings's ANIK Position: Q2 2026 in Review

HSBC Holdings reduced its Anika Therapeutics (ANIK) stake by 0.37% in Q2 2026, selling an estimated $2.77K and leaving 50,105 shares worth $727K. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

HSBC Holdings first reported a position in ANIK in Q2 2020 and has held it in 9 quarters since. The position peaked at $729K in Q1 2026. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • HSBC Holdings held 50,105 shares of Anika Therapeutics worth $727K as of Q2 2026.
  • HSBC Holdings sold 187 Anika Therapeutics shares in Q2 2026, an estimated $2.77K.
  • Anika Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2104 holding.
  • HSBC Holdings first reported a position in Anika Therapeutics in Q2 2020 and has held it in 9 quarters since.
  • HSBC Holdings's Anika Therapeutics position peaked at $729K in Q1 2026.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.